(MENAFN- EIN Presswire) market-scope.jpeg" width="300" height="88" alt="Heplisav B market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034" style="max ...

Ms. Silvernail said, "Dynavax is a clear category leader with its lead asset, HEPLISAV-B, and I am eager to work with the Board to help advance the Company's strategic and financial initiatives to ...

Dynavax Technologies Corporation (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of ...

EMERYVILLE, Kalifornien - Dynavax Technologies Corporation (NASDAQ: DVAX ), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit einer Marktkapitalisierung von 1,67 Milliarden US-Dollar ...

Dynavax Technologies Corporation (NASDAQ: DVAX ), ein profitables Pharmaunternehmen mit solider finanzieller Gesundheit laut InvestingPro-Analyse, gab die Ernennung von zwei neuen Mitgliedern in seine ...

Dynavax Technologies Corporation (NASDAQ:DVAX), a profitable pharmaceutical company with strong financial health according to ...

EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...

An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...

June 12, 2023 — Women who used combined contraceptive pills were at greater risk of developing depression than women who did not, according to a new study. Contraceptive pills increased women's ...

Expert Rev Vaccines. 2008;7(9):1341-1356. © 2008 Expert Reviews Ltd. The authors have no relevant affiliations or financial involvement with any organization or ...

Dynavax Technologies Corporation stock price live, this page displays NASDAQ DVAX stock exchange data. View the DVAX premarket stock price ahead of the market session or assess the after hours quote.